Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bausch Health Companies Inc., Amneal Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson’s disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Latest Pharmaceuticals and Bausch Health Companies Inc., Amneal Pharmaceuticals, Inc. Stock News

As of July 31, 2026, Bausch Health Companies Inc. had a $2.6 billion market capitalization, compared to the Pharmaceuticals median of $579.1 million. Bausch Health Companies Inc.’s stock is down 0.9% in 2026, up 55.5% in the previous five trading days and up 7.83% in the past year.

Currently, Bausch Health Companies Inc. does not have a price-earnings ratio. Bausch Health Companies Inc.’s trailing 12-month revenue is $10.9 billion with a -10.1% net profit margin. Year-over-year quarterly sales growth most recently was 12.7%. Analysts expect adjusted earnings to reach $4.301 per share for the current fiscal year. Bausch Health Companies Inc. does not currently pay a dividend.

As of July 31, 2026, Amneal Pharmaceuticals, Inc. had a $5.8 billion market cap, putting it in the 70th percentile of all stocks. Amneal Pharmaceuticals, Inc.’s stock is up 45.4% in 2026, up 2.2% in the previous five trading days and up 127.01% in the past year.

Currently, Amneal Pharmaceuticals, Inc.’s price-earnings ratio is 49.4. Amneal Pharmaceuticals, Inc.’s trailing 12-month revenue is $3.0 billion with a 5.0% net profit margin. Year-over-year quarterly sales growth most recently was 3.9%. Analysts expect adjusted earnings to reach $0.993 per share for the current fiscal year. Amneal Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Bausch Health Companies Inc.	BHC	A
Amneal Pharmaceuticals, Inc.	AMRX	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Bausch Health Companies Inc. has a Value Score of 95, which is Deep Value. Amneal Pharmaceuticals, Inc. has a Value Score of 36, which is Expensive.

The Value Stock Winner: Bausch Health Companies Inc.

As you can clearly see from the Value Grade breakdown above, Bausch Health Companies Inc. is considered to have better value than Amneal Pharmaceuticals, Inc.. For investors who focus solely on a company’s valuation, Bausch Health Companies Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Bausch Health Companies Inc.	BHC	B
Amneal Pharmaceuticals, Inc.	AMRX	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Bausch Health Companies Inc. has a Quality Score of 76, which is Strong. Amneal Pharmaceuticals, Inc. has a Quality Score of 79, which is Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc. have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Bausch Health Companies Inc.	BHC	B
Amneal Pharmaceuticals, Inc.	AMRX	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Bausch Health Companies Inc. has a Momentum Score of 66, which is Strong. Amneal Pharmaceuticals, Inc. has a Momentum Score of 94, which is Very Strong.

The Momentum Grade Winner: Amneal Pharmaceuticals, Inc.

As you can clearly see from the Momentum Grade breakdown above, Amneal Pharmaceuticals, Inc. is considered to have stronger momentum compared to Bausch Health Companies Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc. Grades

In addition to Quality, Value and Momentum, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bausch Health Companies Inc., Amneal Pharmaceuticals or Inc. Stock?

Overall, Bausch Health Companies Inc. stock has a Value Score of 95, Momentum Score of 66 and Quality Score of 76.

Amneal Pharmaceuticals, Inc. stock has a Value Score of 36, Momentum Score of 94 and Quality Score of 79.

Comparing Bausch Health Companies Inc., Amneal Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.